James D. Brenton

From WikiProjectMed
Jump to navigation Jump to search
James D Brenton
Alma materUniversity College London, University of Cambridge
Scientific career
InstitutionsCancer Research UK Cambridge Institute, University of Cambridge Addenbrooke's Hospital
Websitewww.cruk.cam.ac.uk/research-groups/brenton-group

Professor James D Brenton is a clinician scientist and Senior Group Leader at the Cancer Research UK Cambridge Institute and Professor of Ovarian Cancer Medicine in the Department of Oncology, University of Cambridge.[1] He is an Honorary Consultant in Medical Oncology at Addenbrooke's Hospital, Cambridge University Hospitals,[2] Ovarian Cancer Domain Lead for the 100,000 Genomes Project by Genomics England,[3] and co-founder and Clinical Advisor to Inivata Ltd, a clinical cancer genomics company.[4]

Education and career

Dr Brenton studied Medicine at University College London, graduating in 1988, and trained in Medical Oncology at the Royal Marsden Hospital and Princess Margaret Cancer Centre, Toronto.[5] He completed his PhD at the Gurdon Institute before attaining a Senior Clinical Research Fellowship for his work at the MRC Cancer Unit. In 2007 he became a Senior Group Leader at the Cancer Research UK Cambridge Institute, leading the Functional Genomics of Ovarian Cancer laboratory.

Research

Brenton's research focuses on understanding the molecular complexity of ovarian cancer to improve treatment and patient outcome.[6] His team discovered a ubiquitous TP53 mutation in high grade serous ovarian cancer (HGSOC),[7] the most common form of ovarian cancer, which was adopted as a critical marker for diagnosing HGSOC by the World Health Organisation.[8] Brenton used this TP53 discovery to develop personalised circulating tumour DNA assays to measure treatment response in ovarian cancer.[9][10]

In 2015, his team was the first to measure the tumour heterogeneity in a solid tumour and link this to cancer survival, finding that HGSOC was more deadly if it consisted of a patchwork of different groups of cells.[11][12][13][14][15]

In 2018, Brenton published the first national effort to investigate cancer evolution in HGSOC, discovering seven distinct genetic patterns that could predict disease behaviour in response to treatment.[16][17][18][19] This led to the BriTROC-2 study, funded by Ovarian Cancer Action, to create new, personalised treatments for women with HGSOC.[20]

References

  1. ^ "Dr James Brenton". Cancer Research UK. 2016-07-26. Retrieved 2019-11-18.
  2. ^ "Dr James Brenton | Cambridge University Hospitals". www.cuh.nhs.uk. Retrieved 2019-11-18.
  3. ^ "Genomics England Announce Lead Researchers". Front Line Genomics. Retrieved 2019-11-18.
  4. ^ "New Review of ctDNA Liquid Biopsies in Nature Reviews Cancer Co-Authored by Inivata CSO Nitzan Rosenfeld". Welcome to Inivata. 2017-02-24. Retrieved 2019-11-18.
  5. ^ "Dr James Brenton". Cambridge Clinical Informatics. Retrieved 2019-11-18.
  6. ^ "Research Gate".
  7. ^ Ahmed, Ahmed Ashour; Etemadmoghadam, Dariush; Temple, Jillian; Lynch, Andy G; Riad, Mohamed; Sharma, Raghwa; Stewart, Colin; Fereday, Sian; Caldas, Carlos; deFazio, Anna; Bowtell, David (May 2010). "Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary". The Journal of Pathology. 221 (1): 49–56. doi:10.1002/path.2696. ISSN 0022-3417. PMC 3262968. PMID 20229506.
  8. ^ Duska, L. R.; Kohn, E. C. (2017-11-01). "The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications". Annals of Oncology. 28 (suppl_8): viii8–viii12. doi:10.1093/annonc/mdx445. ISSN 0923-7534. PMC 6246280. PMID 29232468.
  9. ^ Parkinson, Christine A.; Gale, Davina; Piskorz, Anna M.; Biggs, Heather; Hodgkin, Charlotte; Addley, Helen; Freeman, Sue; Moyle, Penelope; Sala, Evis; Sayal, Karen; Hosking, Karen (2016-12-20). "Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study". PLOS Medicine. 13 (12): e1002198. doi:10.1371/journal.pmed.1002198. ISSN 1549-1676. PMC 5172526. PMID 27997533.
  10. ^ "Searching for a blood test to monitor ovarian cancer". Cancer Research UK - Science blog. 20 December 2016. Retrieved 2019-11-18.
  11. ^ Schwarz, Roland F.; Ng, Charlotte K. Y.; Cooke, Susanna L.; Newman, Scott; Temple, Jillian; Piskorz, Anna M.; Gale, Davina; Sayal, Karen; Murtaza, Muhammed; Baldwin, Peter J.; Rosenfeld, Nitzan (2015-02-24). "Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis". PLOS Medicine. 12 (2): e1001789. doi:10.1371/journal.pmed.1001789. ISSN 1549-1676. PMC 4339382. PMID 25710373.
  12. ^ "'Patchwork' ovarian cancer more deadly". Cancer Research UK. 2015-02-24. Retrieved 2019-11-18.
  13. ^ "Ovarian cancer more deadly if in 'patchwork' pattern | Cambridge University Hospitals". www.cuh.nhs.uk. Retrieved 2019-11-18.
  14. ^ "Unpicking the genetic 'patchwork' in ovarian cancer". Cancer Research UK - Science blog. Retrieved 2019-11-18.
  15. ^ "'Patchwork' ovarian cancer is most deadly". The Best Of Health. 4 March 2015. Retrieved 2019-11-18.
  16. ^ Macintyre, Geoff; Goranova, Teodora E.; De Silva, Dilrini; Ennis, Darren; Piskorz, Anna M.; Eldridge, Matthew; Sie, Daoud; Lewsley, Liz-Anne; Hanif, Aishah; Wilson, Cheryl; Dowson, Suzanne (September 2018). "Copy number signatures and mutational processes in ovarian carcinoma". Nature Genetics. 50 (9): 1262–1270. doi:10.1038/s41588-018-0179-8. ISSN 1546-1718. PMC 6130818. PMID 30104763.
  17. ^ "Unravelling ovarian cancer genome complexity – NIHR Imperial Biomedical Research Centre". Retrieved 2019-11-18.
  18. ^ "Ovarian cancer genetics unravelled | Imperial News | Imperial College London". Retrieved 2019-11-18.
  19. ^ "Exciting new research could lead to personalised ovarian cancer treatments". Ovarian Cancer Action. Retrieved 2019-11-18.
  20. ^ "BriTROC-2". Ovarian cancer Action. Retrieved 2019-11-18.
Retrieved from "https://mdwiki.org/wiki/James_D._Brenton"